Compare · BIIB vs QNCX
BIIB vs QNCX
Side-by-side comparison of Biogen Inc. (BIIB) and Quince Therapeutics Inc. (QNCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and QNCX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $29.11B, about 1844.6x QNCX ($15.8M).
- Over the past year, BIIB is up 56.1% and QNCX is down 93.3% - BIIB leads by 149.3 points.
- BIIB has been more active in the news (20 items in the past 4 weeks vs 9 for QNCX).
- BIIB has more recent analyst coverage (25 ratings vs 4 for QNCX).
- Company
- Biogen Inc.
- Quince Therapeutics Inc.
- Price
- $197.18-1.20%
- $0.97+4.56%
- Market cap
- $29.11B
- $15.8M
- 1M return
- +4.01%
- -9.62%
- 1Y return
- +56.06%
- -93.28%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 20
- 9
- Recent ratings
- 25
- 4
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
- Director Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)
- Director Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)
- Director Rowinsky Eric K was granted 1,505 shares, increasing direct ownership by 6% to 25,844 units (SEC Form 4)
- Director Mantas Jesus B was granted 1,505 shares, increasing direct ownership by 15% to 11,263 units (SEC Form 4)
- Director Langer Susan was granted 1,505 shares, increasing direct ownership by 29% to 6,634 units (SEC Form 4)
- Director Patolawala Monish D was granted 1,505 shares, increasing direct ownership by 41% to 5,215 units (SEC Form 4)
- Director Pangalos Menelas N converted options into 2,370 shares and was granted 1,505 shares (SEC Form 4)
Latest QNCX
- Cantor Fitzgerald initiated coverage on Quince Therapeutics with a new price target
- SEC Form 4 filed by Director Lamond David
- SEC Form 4 filed by Director Senner Christopher J.
- SEC Form 4 filed by Chief Corp. Affairs Officer Roberts Brigette
- SEC Form 3 filed by new insider Roberts Brigette
- SEC Form 8-K filed by Quince Therapeutics Inc.
- SEC Form D filed by Quince Therapeutics Inc.
- SEC Form D filed by Quince Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.
- SEC Form 8-K filed by Quince Therapeutics Inc.